Table 2.
Costs and health outcomes associated with 70% coverage and adherence in a hypertension control intervention for individuals between 40–69 yrs from 2020–40
| ICER ($/DALY averted, 95% UI) | DALYs Averted (percent, 95% UI) | CVD Events Averted (percent, 95% UI) | Per-capita incremental costs over 20 years^ | Annual net expenditure^,ψ (in ‘000 US $) | Proba-bility of Cost Saving# | ||||
|---|---|---|---|---|---|---|---|---|---|
| Female | Male | Female | Male | Female | Male | Antihypertensive Treatment ($, 95% UI) | CVD Treatment ($, 95% UI) | ||
| Cost-saving | Cost-Saving | 2.17 (2.15 to 2.19) |
1.30 (1.29 to 1.32) |
5.85 (5.82 to 5.89) |
3.78 (3.75 to 3.81) |
18.04 (17.95 to 18.13) |
–19.43 (–19.55 to –19.3) |
–$26,740 | 0.721 |
The results are based on 1000 simulation runs with a time horizon of 20 years in two hypothetical cohorts of 10,000 individuals (males and females respectively) with ages 40–69 yrs at the start of the simulation. The status quo is based on 17% coverage, 30% adherence, and the NPCDCS medication guideline.
^ Negative values indicate cost-saving, i.e., lower expenditure compared to status quo, and the values are calculated based on the estimated Indian population of age 40–69 yrs in 2020.
ψ The estimated population of age 40–69 yrs in 2020 was used to calculate the annual expenditure for the population.
# The probability of cost-saving was calculated based on the number of simulations runs which saved overall costs among the 1000 simulation runs.